Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to 74.4%

Operating margin was 74.4% in Q2 FY2026, up 832.4 pp from a year earlier. On a trailing-twelve-month basis it was 20.7%, up 9.2 pp year over year. Over 3 fiscal years it widened by 150.6 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 9 analysts of 81.1% for the fiscal year ending Dec 2026, up from -343.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
74.4%+80.8 pp QoQ
Last fiscal yearDec 2025
-343.6%-401.8 pp YoY
LTMJun 2026
20.7%+9.2 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+832.4 pp+1096.7 pp+264.3 pp
1 year-401.8 pp+424.7 pp+826.6 pp
3 years+150.6 pp+394.9 pp+244.3 pp
5 years+412.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-343.6%
Year-over-year change
-401.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 operating margin of 20.7% is the highest of the 5 companies compared; the peer median is -619.2%.
  • Its year-over-year change of +9.2 pp is the 2nd highest of 3, against a peer median of -30.6 pp.
  • Over three fiscal years its change of +150.6 pp compares with a peer median of +233.0 pp.
PTGX Competitors Peer median
Operating Margin for PTGX and competitors
Company Period LTM level YoY 3-year change
PTGXProtagonist Therapeutics, Inc.LTM Jun 202620.7% +9.2 pp+150.6 pp
ANABAnaptysBio, Inc.LTM Mar 202617.6% +107.2 pp+1139.8 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-276.5% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-961.9% -168.3 pp-673.9 pp
IMVTImmunovant, Inc.LTM Sep 2026-7488.4% ——
IRONDisc Medicine, Inc.FY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding PTGX) -619.2%-30.6 pp+233.0 pp

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.36M26.58M60M434.43M46.02M
Cost of Revenue00001.23M
Gross Profit27.36M26.58M60M434.43M44.79M
Gross Margin100.0%100.0%100.0%100.0%97.3%
Research & Development126.01M126.22M120.16M138.13M159.29M
Selling, General & Admin27.2M31.74M33.49M43.46M44.85M
Operating Expenses153.2M157.95M153.65M181.59M202.92M
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
EBITDA(122.78M)(124.02M)(75.64M)282.37M(128.03M)
EBITDA Margin-448.8%-466.6%-126.1%65.0%-278.2%
Operating Income(125.85M)(131.37M)(93.65M)252.84M(158.13M)
Operating Margin-460.0%-494.2%-156.1%58.2%-343.6%
Interest Income443K4.06M14.9M26.32M28.79M
Interest Expense00000
Other Income / Expenses294K3.98M14.7M26.57M28.82M
Income Before Tax(125.55M)(127.39M)(78.96M)279.41M(129.31M)
Pre-Tax Margin-458.9%-479.3%-131.6%64.3%-281.0%
Income Tax Expense0004.22M838K
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Net Margin-458.9%-479.3%-131.6%63.3%-282.8%
EPS (Basic)(2.65)(2.52)(1.39)4.47(2.05)
EPS (Diluted)(2.65)(2.52)(1.39)4.23(2.05)
Weighted Avg Shares46.32M49.04M56.76M61.57M63.57M
Weighted Avg Shares (Diluted)46.32M49.04M56.76M65.08M63.57M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.